CRISPR/Cas9 screens identify key host factors that enhance rotavirus reverse genetics efficacy and vaccine production

Yinxing Zhu1, Meagan E Sullender2, Danielle E Campbell2

  • 1Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA.

NPJ Vaccines
|November 6, 2024
PubMed

Insights

Researchers identified SERPINB1 and TMEM236 as key antiviral factors against rotaviruses. Enhancing cell lines with these gene knockouts improves rotavirus recovery and vaccine production efficiency.

Area of Science:

  • Virology
  • Genetics

Background:

  • Rotaviruses are a major cause of severe diarrhea in infants globally.
  • Identifying host factors influencing rotavirus replication is crucial for therapeutic and vaccine development.

Purpose of the Study:

  • To discover novel host factors affecting rotavirus replication using genome-wide CRISPR screens.
  • To optimize rotavirus reverse genetics systems and develop improved cell substrates for vaccine production.

Main Methods:

  • Genome-wide CRISPR/Cas9 screening in African green monkey cells (MA104) with rhesus rotavirus.
  • Genetic deletion of identified antiviral factors (SERPINB1, TMEM236) in MA104 and Vero cells.
  • Optimization of rotavirus reverse genetics systems using SERPINB1 knockout cells.
  • Evaluation of TMEM236 knockout Vero cells for live-attenuated rotavirus vaccine production.

Main Results:

  • SERPINB1 and TMEM236 were identified as potent antiviral factors, with their deletion increasing rotavirus titers.
  • An optimized third-generation rotavirus reverse genetics system was developed, enhancing recovery of difficult strains.
  • TMEM236 knockout Vero cells demonstrated significantly higher yields for live-attenuated rotavirus vaccine strains compared to parental cells.

Conclusions:

  • SERPINB1 and TMEM236 are critical host factors for controlling rotavirus infection.
  • The developed reverse genetics system and gene-edited Vero cells represent significant advancements for rotavirus research and vaccine manufacturing.